20Jun/13

Two Studies Evaluating the Combination of REVLIMID(R) and rituximab in Non … – MarketWatch (press release)

Monoclonal Anti-CD20 Antibodies

Two Studies Evaluating the Combination of REVLIMID(R) and rituximab in Non …
MarketWatch (press release)
Celgene International Sarl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) , today announced that results from two studies evaluating the combination of REVLIMID(R) (lenalidomide) and rituximab in various non-Hodgkin’s lymphomas …
Two Studies Evaluating the Combination of REVLIMID ® and rituximab in Non …EON: Enhanced Online News (press release)

all 3 news articles »
19Jun/13

GILEAD SCIENCES, INC. : Gilead Announces Interim Phase 2 Data for Idelalisib … – 4-traders (press release)

Monoclonal Anti-CD20 Antibodies

GILEAD SCIENCES, INC. : Gilead Announces Interim Phase 2 Data for Idelalisib …
4-traders (press release)
… idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin’s lymphoma (iNHL) that is refractory (non-responsive) to rituximab and to alkylating-agent-containing …
Gilead Presents Idelalisib DataZacks.com

all 2 news articles »
17Jun/13

New EXTEND Analyses Evaluate Efficacy Of Single Agent PIXUVRI® In 3rd And … – Daily Markets

Monoclonal Anti-CD20 Antibodies

New EXTEND Analyses Evaluate Efficacy Of Single Agent PIXUVRI® In 3rd And …
Daily Markets
Compared to physicians’ choice of other agents given as monotherapy, single agent PIXUVRI resulted in 30 percent of patients who had previously received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 …

and more »
17Jun/13

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI(R) in 3rd … – Wall Street Journal (press release)

Monoclonal Anti-CD20 Antibodies

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI(R) in 3rd …
Wall Street Journal (press release)
Compared to physicians’ choice of other agents given as monotherapy, single agent PIXUVRI resulted in 30 percent of patients who had previously received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 …

and more »
17Jun/13

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI in 3rd and … – MarketWatch (press release)

Monoclonal Anti-CD20 Antibodies

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI in 3rd and …
MarketWatch (press release)
Compared to physicians’ choice of other agents given as monotherapy, single agent PIXUVRI resulted in 30 percent of patients who had previously received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 …

and more »
17Jun/13

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI® in 3rd and … – PR Newswire (press release)

Monoclonal Anti-CD20 Antibodies

New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI® in 3rd and …
PR Newswire (press release)
Compared to physicians’ choice of other agents given as monotherapy, single agent PIXUVRI resulted in 30 percent of patients who had previously received rituximab achieving a complete or unconfirmed durable complete response lasting on average 9.5 …

and more »
14Jun/13

Zusetzen von Obinutuzumab (GA101) oder Rituximab zu Chlorambucil … – FinanzNachrichten.de (Pressemitteilung)

Monoclonal Anti-CD20 Antibodies

Zusetzen von Obinutuzumab (GA101) oder Rituximab zu Chlorambucil …
FinanzNachrichten.de (Pressemitteilung)
Zugehörigkeit: Deutsche CLL-Studiengruppe, Köln, Deutschland Thema: Zusetzen von Obinutuzumab (GA101) oder Rituximab zu Chlorambucil verbessert Aussichten für ältere Patienten mit chronischer lymphatischer Leukämie (CLL) und Komorbiditäten …

and more »